Gene test could predict leukemia relapse and guide treatment
NCT ID NCT02756962
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 21 times
Summary
This study looks at whether checking for specific genetic mutations in patients with acute myeloid leukemia (AML) after chemotherapy can better predict their risk of relapse. About 107 adults aged 18-60 with intermediate-risk AML will have their blood or bone marrow tested for leukemia-related mutations. The goal is to see if those who clear these mutations have better survival, and to guide treatment decisions for those who don't.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.